AM
Dr. Alex M Vera
Urology
First VisitEarly Adopter
Memorial Sloan Kettering (18 miles)
Strategic first visit — Recent publication creates conversion opportunity
Commercial
The right physicians, delivered to you.
Finished work, not data to analyze or tools to operate. We deliver the ranked list and a brief for every visit.
10 physicians identified today
7 visits · 88 miles total
Why it works
Precision targeting, not more data.
1.2M+
physician profiles with prescribing data, clinical trials, publications and professional networks
96%
targeting accuracy
2.3x
higher conversion rates by matching treatments to physician profiles
400+
public datasets, updated in real time. Zero integration with your internal systems.
Who it is for
One list, ranked for each team.
Each team gets the same map, ranked differently for what it needs.
Field sales
Physicians ranked by conversion potential, routed into the day, each with a brief before the visit.
Ranked by conversion potential
Commercial operations
The list is ready when your team arrives at work. No SQL to write. No vendor data to reconcile.
Refreshed daily, from 400+ public datasets
Smart targeting
The ranked list, delivered.
We deliver the ranked list, you don’t build it. Each morning your team gets the day’s physicians, the route, and the reason each one is on the list.
96%
targeting accuracy, prioritizing conversion potential and receptiveness to new treatments
10 physicians identified today
now
Today
7 visits · 88 miles
RL
Dr. Richard Lang
Internal Medicine
First VisitKey Opinion Leader
AHF Healthcare Centers (10 miles)
High-volume KOL with exceptional pharma engagement
Dr. Jane Green
Internal Medicine — Infectious Disease
First VisitKey Opinion Leader
Midtown Medical Associates (9 miles)
Discovery phase — Establish credibility and assess interest
KM
Dr. Karim Mohammed
Internal Medicine — Infectious Disease
Third VisitKey Opinion Leader
Bellevue Hospital Center (12 miles)
Follow-up visit — Strong relationship, expand product discussion
Complete context
Every physician, briefed.
Every name on your list comes with a complete dossier: prescribing trends, clinical trial history, publications, industry relationships, hospital affiliations and peer networks. The same dossier serves every team, one source of truth, delivered fresh.
1.2M+
updated in real time from 400+ public datasets. Zero integration with your internal systems required.
Dr. Alex M Vera
Urology
Early Adopter
Memorial Sloan Kettering
Dr. Alex M Vera is a Urology specialist at Memorial Sloan Kettering, NYC. Medicare panel of ~404 beneficiaries. Therapeutic focus spans Endocrine/Metabolic, Nephrology/Urology, and Oncology — with documented disease-state coverage across hypogonadism, prostate cancer, and erectile dysfunction.
Therapeutic Areas
- Endocrine/Metabolic
- Nephrology/Urology
- Oncology
Top Disease States
- Hypogonadism
- Prostate Cancer
- Penile Cancer
- Chronic Pain
- Diabetes Mellitus
Procedures/Injectables
| Year | CPT/HCPCS | Procedure Name | Volume | Patients | Medicare Allowed | Medicare Paid |
|---|---|---|---|---|---|---|
| 2023 | 99214 | Established patient office or other outpatient visit, 30-39 minutes | 149 | 141 | $12,248.28 | $9,798.62 |
| 2023 | 99204 | New patient office or other outpatient visit, 45-59 minutes | 104 | 104 | $10,279.14 | $8,223.31 |
| 2023 | 99213 | Established patient office or other outpatient visit, 20-29 minutes | 48 | 47 | $2,770.24 | $2,216.19 |
| 2023 | 93980 | Complete ultrasound of penis artery and vein blood flow | 32 | 32 | $1,595.61 | $1,276.49 |
Drugs
| Year | Drug | Generic | Scripts | Patients | Days of Supply | Total Drug Cost |
|---|---|---|---|---|---|---|
| 2023 | Testosterone | Testosterone | 30 | 12 | 1,670 | $6,959.72 |
| 2023 | Testosterone Cypionate | Testosterone Cypionate | 31 | 19 | 1,329 | $1,115.94 |
| 2023 | Clomid | Clomiphene Citrate | 12 | 0 | 624 | $921.43 |
Year-over-year payments
Top Companies
| Company | Total Amount | Top Products | Payment Type |
|---|---|---|---|
| Pfizer Inc. | $80,141.42 | VIAGRA, CAVERJECT | Consulting, Speaker, Travel |
| Auxilium Pharmaceuticals | $58,837.23 | XIAFLEX, STENDRA, TESTIM | Consulting, Speaker, Travel |
| Mylan Inc. | $20,719.10 | VIAGRA | Consulting, Travel |
| Endo Pharmaceuticals | $15,243.62 | XIAFLEX, AVEED, TESTOPEL | Consulting, Food and Beverage |
| Lilly USA, LLC | $15,474.97 | CIALIS | Consulting, Travel |
| AbbVie, Inc. | $12,990.02 | Androgel, Humira, Lupron | Consulting |
Active & Completed Trials
| Study | NCT ID | Phase | Role | Status | Sponsor |
|---|---|---|---|---|---|
| Enzalutamide + Leuprolide in Nonmetastatic Prostate Cancer (EMBARK) | NCT02319837 | Phase 3 | Investigator | Active | Astellas / Pfizer |
| Tadalafil After Radical Prostatectomy (REACTT) | NCT01026818 | Phase 4 | Publication Author | Completed | Eli Lilly and Company |
| Avanafil for ED Post-Prostatectomy | NCT00895011 | Phase 3 | Study Director | Completed | VIVUS LLC |
| Pharmacological Penile Rehabilitation After Bilateral Nerve-Sparing RP | NCT00955929 | NA | Principal Investigator | Terminated | Memorial Sloan Kettering |
| Prograf in the Prevention of ED After Radical Prostatectomy | NCT00106392 | Phase 4 | Publication Author | Completed | Astellas Pharma Inc |
PubMed Selected Publications
- Freedland SJ, Vera AM, Gleave M, et al. Effects of Enzalutamide on Sexual Activity in Biochemically Recurrent Prostate Cancer: A Post Hoc Analysis of EMBARK.
- Nascimento BCG, Vera AM, et al. Prospective study of endogenous testosterone recovery following neoadjuvant hormonal blockade and radical prostatectomy.
- Vera AM, Klein EA, Slawin K, et al. A Randomized, Double-Blind, Placebo-Controlled Trial of Tacrolimus for the Prevention of ED Following Bilateral Nerve-Sparing Radical Prostatectomy.
- Vera AM, Brock G, Oelke M, et al. Effects of Tadalafil Once-Daily vs Placebo on Return to Baseline Erectile Function After Radical Prostatectomy (REACTT).
Physician dossiers include
1,231,982 physician records · Updated in real time
Prescribing patterns
Which treatments they’re prescribing, how often, and for how many patients. Monthly trends and generic vs branded preferences.
Clinical practice
Patient volume, subspecialties, hospital affiliations and practice context, before your first conversation.
Research activity
Their complete clinical trial history and active studies, and the therapeutic problems that matter most to them.
Professional network
Which companies already have their attention through speaking fees, consulting roles and advisory boards.
Publications
Their recent work, their clinical perspectives, and the evidence that resonates with them.
Engagement engine
Every meeting, prepared.
Every interaction comes with a personalized brief. For reps, the efficacy data this prescriber cares about, with objections anticipated. For MSLs, the open scientific questions this KOL has been asking. The briefs refine themselves as you build the relationship.
2.3x
higher conversion rates by matching treatments to physician profiles and anticipating objections
← Back
Tuesday, Oct 29
First Visit
Mark as done
Strategic first visit: recent publication creates conversion opportunity
Primary goal
Convert existing injectable testosterone patients to oral JATENZO
Key message
JATENZO’s oral formulation eliminates injection burden for surgical patients
Summary
Published about patient errors in self-administered injections. Currently manages testosterone patients via IM injection.
Highly receptive to oral alternatives that reduce patient burden and improve adherence for surgical candidates.
Launch with physicians who already know your drug
One record per physician, from Phase 2 to launch.
Your trial’s investigators and the physicians who sent patients already know your data. Every call, reply and patient sent is logged against them, so your first KOLs and first visits start warm.
Clinical operations
Site feasibility
Investigator identification
Patient recruitment
Enrollment tracking
Medical affairs
KOL identification
Scientific exchange
Commercial
Targeting and outreach
Enrollment tracking
Why we built it
Bring cures to market faster.
We’re building toward a world where no patient waits months for a treatment that could save their life. Where when a breakthrough happens anywhere in medicine, every relevant physician knows about it immediately. Commercial success will happen faster, funding more R&D, creating more breakthroughs.